Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sangoma Technologies Corporation (SANG : NSDQ)

• Company Description    Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a genomic medicines pipeline. Sangamo Therapeutics is based in BRISBANE, Calif. Number of Employees: 570

• Price / Volume Information    Yesterday's Closing Price: $8.06 Daily Weekly Monthly 20 Day Moving Average: 985 shares Shares Outstanding: 20.57 (millions) Market Capitalization: $165.76 (millions) Beta: 52 Week High: $25.55 52 Week Low: $8.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -40.03% -34.34% 12 Week -35.42% -27.42% Year To Date -52.21% -41.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 Renfrew Drive Suite 100 - MARKHAM,A6 L3R 9R6 CAN ph: 800-388-2475 fax: - investorrelations@sangoma.com http://www.sangoma.com

• General Corporate Information    Officers William Wignall - Chief Executive Officer and President Norman A. Worthington - Chairman David Moore - Chief Financial Officer Marc Lederman - Director Allan Brett - Director Peer Information Sangoma Technologies Corporation (CORR.) Sangoma Technologies Corporation (RSPI) Sangoma Technologies Corporation (CGXP) Sangoma Technologies Corporation (BGEN) Sangoma Technologies Corporation (GTBP) Sangoma Technologies Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 80100R408 SIC: 6770 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/22 Next Expected EPS Date: 10/05/22 Share - Related Items Shares Outstanding: 20.57 Most Recent Split Date: (:1) Beta: Market Capitalization: $165.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.42 Price/Cash Flow: - Price / Sales: 0.78 EPS Growth vs. Year Ago Period: -2,200.00% vs. Previous Quarter: -162.50% Sales Growth vs. Year Ago Period: 96.98% vs. Previous Quarter: 1.63% ROE 03/31/22 - -4.48 12/31/21 - -2.26 09/30/21 - -1.40 ROA 03/31/22 - -3.05 12/31/21 - -1.56 09/30/21 - -0.95 Current Ratio 03/31/22 - 0.70 12/31/21 - 0.97 09/30/21 - - Quick Ratio 03/31/22 - 0.50 12/31/21 - 0.78 09/30/21 - - Operating Margin 03/31/22 - -7.97 12/31/21 - -4.47 09/30/21 - -2.47 Net Margin 03/31/22 - -6.04 12/31/21 - -4.29 09/30/21 - -2.26 Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 19.06 12/31/21 - - 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.26 12/31/21 - 0.19 09/30/21 - - Debt-to-Capital 03/31/22 - 20.45 12/31/21 - 16.11 09/30/21 - -

Powered by Zacks Investment Research ©